Prospects of a 2020 market arrival for Novo Nordisk AS’s ground-breaking oral GLP-1 diabetes therapy remain on track, propelled by solid clinical trial data and a priority review voucher purchased by the Denmark-based group to speed the process.
Regulatory plans for oral semaglutide were announced along with the company’s fourth-quarter and full-year update for fiscal 2018, which although...






